GoodRx Holdings, Inc. (NASDAQ: GDRX) reported upbeat fourth-quarter FY23 results and issued first-quarter revenue guidance above estimates.
Revenue and adjusted revenue increased 7% Y/Y to $196.6 million, beating the consensus of $195.8 million. Adjusted EBITDA rose to $57.3 million from $49.6 million, led by higher prescription transactions revenue, with margin expanding to 29.1% from 26.9%. Adjusted EPS of 8 cents beat the consensus of 7 cents, according to data from Benzinga Pro.
On Feb. 27, 2024, the board of directors approved a new stock repurchase program that authorized the repurchase of up to $450 million of shares.
"We’ve locked in on creating value for consumers and ended the year strong ...